Search PubMed⌕ Search

Biomedical subjects

H B Levy

Publications and source records attributed to H B Levy.

At least 19 recordsLinked to original sources
PubMed1992

A practical approach to children failing in school.

The most likely causes of failure in school in otherwise capable children who come from homes in which they are loved and cared for are learning disabilities, affective illness, primary disorder of vigilance and, on occasion, narcolepsy. The various learning disabilities are often accompanied by problems of attention, concentration, organization, mood and feelings, and social interaction. These latter problems are reflections of biochemical disorders that respond effectively to judicious pharmacologic intervention. When this type of medical management is combined with constructive counseling and suitable curriculum adjustments, the child can attain his or her maximum education potential and become a productive and contributing adult member of society.

Attention Deficit Disorder with Hyperactivity↗
PubMed1992

A comparison of interferon responses to poly ICLC in males and females.

Interferon (IFN) responses to polyriboinosinic acid polyribocytidylic acid in poly-L-lysine and carboxymethylcellulose (poly ICLC) have been studied in detail in 6 men and 3 women as part of a preliminary trial in patients with multiple sclerosis (MS). Patients received intravenous (i.v.) doses of 100 micrograms/kg poly ICLC, and serum IFN levels were determined serially every 4 h for 16 h. Men and women produced substantial levels of IFN at 8, 12, and 16 h after infusion, but levels in men were consistently and significantly higher (p less than 0.05). Interferon responses were examined also in 3 male and 3 female Rhesus monkeys. Serum samples were obtained 8 and 24 h after i.v. injections of 1 mg/kg of poly ICLC. Again, there were significantly higher levels of IFN in males. The observed differences may reflect sex-linked differences in either drug metabolism or specific sensitivity to IFN induction by poly ICLC. The most interesting possibility is that the difference is due to a more general difference in IFN response between males and females. Studies are currently in progress to evaluate these possibilities.

Adult↗
PubMed1991

Changes in leukocyte recirculation, NK cell activity, and HLA-DR expression in peripheral blood mononuclear cells of MS patients treated with Poly ICLC.

To investigate the cellular immune effects of the interferon inducer, Poly ICLC, in humans, peripheral blood mononuclear cells from patients with multiple sclerosis receiving Poly ICLC as part of a preliminary clinical trial were studied. Peripheral blood mononuclear cell phenotype analysis using fluoresceinated monoclonal antibodies and flow microfluorometry showed decreases in the percentages and absolute numbers of all lymphocyte subsets 24 h after infusion. These changes returned toward baseline at 48 h except the percentage of CD-4 positive cell which increased above baseline levels. The percentage of HLA-DR antigen positive cells and CD-16 (Leu 11a) positive cells were increased 24 h after infusion but returned to baseline at 48 h. NK activity as determined by chromium release from K562 target cells was decreased at 24 h but increased 48 h after drug infusion. The increases in percentages of HLA-DR antigen and CD-16 positive cells at 24 h and NK activity at 48 h are consistent with the in vitro effects of IFN while the decreases in peripheral blood mononuclear cells are suggestive of changes in cell recirculation.

Antigens, CD↗
PubMed1991

Gamma-interferon induction in patients with chronic progressive MS.

Although gamma interferon (gamma-IFN) may be involved in the pathogenesis of exacerbations of multiple sclerosis (MS), whether it plays a role in chronic progressive MS is not known. To investigate this, we retrospectively analyzed serum samples from nine chronic progressive MS patients who were treated with monthly intravenous infusions of the interferon inducer polyinosinic acid polycytidylic acid polylysine in carboxymethylcellulose (poly ICLC). Using a bioassay we found that the mean peak total interferon level was 177 U/ml 12 hours after infusion, and using a radioimmunoassay we found that the mean peak gamma-IFN level was 15.9 U/ml 12 hours after infusion, so that gamma-IFN made up approximately 10% of the total. Greater gamma-IFN induction did not correlate with clinical worsening; induced gamma-IFN levels were not higher in two patients who worsened on treatment, and the highest levels were found in a patient who remained stable. Either chronic progressive MS is not sensitive to gamma-IFN or the effects of gamma-IFN are masked by other mediators induced by poly ICLC.

Antigens, CD↗
PubMed1989

Postinfection therapy of arbovirus infections in mice.

Most antiviral agents are efficacious prophylactically in vivo, and a few are efficacious for postinfection (p.i.) therapy. To explore possibilities for p.i. therapy of encephalogenic Banzi virus (BZV) and Semliki Forest virus infections in mice, we evaluated candidate antiviral therapies after development of the first clinical signs of infection. The earliest clinical indication of BZV viremia in mice is a rise in core body temperature beginning on day 3 p.i. BZV-infected mice showing elevated core body temperatures (greater than or equal to 37.3 degrees C) on days 3 and 4 p.i. were treated intraperitoneally with the interferon inducer poly(ICLC) (80 micrograms per mouse) and/or specific antiserum. Combined therapy on day 3 of a BZV infection protected over 75% of mice showing clinical evidence of viral disease before treatment. Protection against early brain infection must occur on day 4 p.i., since by that day BZV has started multiplying in the brains of the mice. Significant protection occurred with antiserum alone and increased with poly(ICLC). Similar protection was obtained during Semliki Forest virus viremia, but this infection is so rapid that the first clinical signs are reliably detectable only after viremia.

Animals↗
PubMed1988

Cortisol induction by poly ICLC: implications for clinical trials of interferon.

Because interferon injections have recently been reported to induce cortisol in cancer patients, we retrospectively reviewed cortisol levels obtained during a preliminary trial of the interferon inducer polyriboinosinic polyribocytidylic acid in poly-L-lysine and carboxymethylcellulose (poly ICLC) in multiple sclerosis patients to determine if significant cortisol induction occurred. Analysis of data from 51 poly ICLC infusions in 6 men and 4 women showed elevated cortisol levels 4 to 16 hours after infusion, with hematological changes consistent with steroid effect. The highest cortisol levels observed were in 2 patients who improved during the treatment period, but there was no clear relationship between cortisol levels and clinical outcome in the group as a whole.

Adult↗
PubMed1988

The kinetics of interferon induction by poly ICLC in humans.

A preliminary trial of the interferon (IFN) inducer polyriboinosinic acid-polyribocytidylic acid in poly-L-lysine and carboxymethylcellulose (poly ICLC) was conducted in patients with chronic progressive multiple sclerosis (MS). Because IFN induction in men is greater than in women, the kinetics of IFN induction were studied. As no significant differences were found in the serum half-life of IFN, sex-linked differences in IFN clearance or degradation are not likely to be responsible for the differences noted. Because fever was the major limiting side effect in MS patient, the relationship of fever to IFN levels was assessed. Changes in temperature were not related to changes in IFN levels, suggesting that fever might be blocked without reducing IFN levels.

Carboxymethylcellulose Sodium↗
PubMed1987

Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice.

The therapeutic efficacy of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine and carboxymethyl cellulose [poly(ICLC)] given alone or in combination with ribavirin was evaluated in Swiss Webster mice infected with Rift Valley fever virus. Four or more 20-micrograms doses of poly(ICLC) given at various intervals beginning 24 h after infection protected all mice against death. On the other hand, a treatment regimen consisting of only three doses of poly(ICLC) given 24 h postinfection resulted in a 50% survival rate. When initiated 48 h postinfection, an extended treatment regimen with the same dose was required to yield 40% survivors. Lower doses (5 micrograms) of poly(ICLC) per mouse were only marginally effective even when six injections were given between days 1 and 9 postinfection. The combined administration of ribavirin and poly(ICLC) initiated as late as 48 h postinfection was effective even when treatment consisted of doses that were ineffective when either drug was used alone.

Animals↗
PubMed1987

Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death.

The prophylactic efficacy of poly(ICLC) (stabilized, synthetic, double-stranded polyriboinosinic-polyribocytidylic acid) against Rift Valley fever virus infection in Swiss-Webster mice was dependent on the treatment schedule. The treatment schedule was optimized by ranking the results of various treatments by the Cox proportional-hazard model based on the incremental relative risk of death. With this ranking procedure, the schedule of choice was three doses of 20 micrograms each given 5 days apart. This regimen yielded a 90% survival rate. Additional parameters were determined, including the timing of the first and second drug dose, the temporal relationship of these treatments to the day of challenge, and the minimal effective dose (1 microgram per mouse).

Animals↗
PubMed1986

Preliminary trial of poly ICLC in chronic progressive multiple sclerosis.

Eighteen patients with chronic progressive multiple sclerosis (MS) were treated in an open preliminary trial of the interferon inducer and immune modulator, poly ICLC. All patients produced substantial interferon levels and experienced acute side effects, including fever and transient worsening of neurologic symptoms. Of nine patients with rapid neurologic deterioration at the time of entry into the study, only three had disease progression during treatment. We conclude that poly ICLC can be administered safely to MS patients, and that a controlled trial will be necessary to determine efficacy.

Adult↗
PubMed1985

Child abuse reporting.

Explore the source record for details and available documents.

Attitude of Health Personnel↗
PubMed1985

Response of mouse tumor to interferon inducer and radiation.

The antitumor effect of interferon inducer poly(ICLC), given prior to the radiation treatment of Lewis lung carcinoma in C57Bl mice was studied. To induce the tumors, the mice were injected subcutaneously into the hind leg with 3 X 10(4) or 3 X 10(5) tumor cells. The combination treatment consisted of poly(ICLC) given at 1.25 mg/kg 6 hours before 400 cGy of 60Co gamma rays. All treatments were given three times over 1.5 weeks. The local response, as measured by the delay in the tumor growth, was significantly higher in the combination treatment group than in poly(ICLC) or local irradiation groups. Following the termination of treatment, tumor regrowth was observed. The survival of poly(ICLC) treated mice was influenced by the number of transplanted tumor cells. Thus, untreated mice which received 3 X 10(4) or 3 X 10(5) (2 or 20 TD50) of tumor cells had similar mean survival time of 25.4 +/- 1.9 and 22 +/- 84 days, respectively (p greater than 0.05). The mice, treated by a combination of poly(ICLC) and local irradiation survived 48.2 +/- 2.1 days and 30.7 +/- 1.2 days (p less than .01), with higher survival in 2 TD50 tumor cell groups. Thus, data obtained in this study in mice showed that administration of an interferon inducer poly(ICLC) prior to local irradiation can improve tumor response and survival.

Animals↗
PubMed1985

Alopecia in meralgia paresthetica.

Meralgia paresthetica has been described as a common affliction of the lateral femoral cutaneous nerve, creating the symptoms of numbness, tingling, and paresthesias in the overlying areas of the lateral and anterior thigh. It is second only to sciatica in peripheral nerve diseases of the lower extremity. We present two patients with classic symptoms of meralgia paresthetica and nonscarring alopecia overlying and demarcating the areas of paresthesias. Meralgia paresthetica should be included in the differential diagnosis of localized alopecia of the anterior or lateral thigh.

Aged↗
PubMed1985

A comparison of interferon responses to poly ICLC in males and females.

Interferon (IFN) responses to polyriboinosinic acid polyribocytidylic acid in poly-L-lysine and carboxymethylcellulose (poly ICLC) have been studied in detail in 6 men and 3 women as part of a preliminary trial in patients with multiple sclerosis (MS). Patients received intravenous (i.v.) doses of 100 micrograms/kg poly ICLC, and serum IFN levels were determined serially every 4 h for 16 h. Men and women produced substantial levels of IFN at 8, 12, and 16 h after infusion, but levels in men were consistently and significantly higher (p less than 0.05). Interferon responses were examined also in 3 male and 3 female Rhesus monkeys. Serum samples were obtained 8 and 24 h after i.v. injections of 1 mg/kg of poly ICLC. Again, there were significantly higher levels of IFN in males. The observed differences may reflect sex-linked differences in either drug metabolism or specific sensitivity to IFN induction by poly ICLC. The most interesting possibility is that the difference is due to a more general difference in IFN response between males and females. Studies are currently in progress to evaluate these possibilities.

Animals↗
PubMed1985

Historical overview of the use of polynucleotides in cancer.

A search for effective inducers of interferon lead to the discovery of polyinosinic-polycytidylic acid [poly(I,C)], which was effective in rodents but not primates. Stabilization of poly(I,C) with poly-L-lysine and carboxymethyl-cellulose produced a derivative that is much more effective as an inducer in humans, but also more toxic. The ability of modified poly(I,C) to induce interferon in primates appears to be at least partly related to its ability to resist hydrolysis by nucleases. As the ability to induce interferon in primates increases, so does the toxicity. Several investigations have emphasized increasing the ease of hydrolysis in order to minimize toxicity. The inducers should not be considered just as a readily available source of interferon, as there are a number of differences between the biologic effects of the inducers and exogenous interferon.

Animals↗